Immunovant (IMVT) Stock Forecast & Price Target

$25.86 +0.20 (+0.78%)

(As of 12/20/2024 05:31 PM ET)

Immunovant - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 10 Analyst Ratings

Sell
0

Hold
0

Buy
10

Based on 10 Wall Street analysts who have issued ratings for Immunovant in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 10 have given a buy rating for IMVT.

Consensus Price Target

$47.22
82.61% Upside

According to the 10 analysts' twelve-month price targets for Immunovant, the average price target is $47.22. The highest price target for IMVT is $55.00, while the lowest price target for IMVT is $36.00. The average price target represents a forecasted upside of 82.61% from the current price of $25.86.

Get the Latest News and Ratings for IMVT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Immunovant and its competitors.

IMVT Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	11 Buy rating(s)	15 Buy rating(s)	14 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$47.22	$48.10	$48.40	$45.07
Forecasted Upside	82.61% Upside	81.24% Upside	65.58% Upside	8.66% Upside
Consensus Rating	Buy	Buy	Buy	Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

IMVT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immunovant Stock vs. The Competition

Type	Immunovant	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	82.61% Upside	25,828.56% Upside	14.54% Upside
News Sentiment Rating	Neutral News See Recent IMVT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/19/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$47.00 ➝ $45.00	+72.28%
11/8/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$51.00 ➝ $51.00	+70.40%
10/10/2024	Raymond James 4 of 5 stars	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00	+15.38%
10/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$47.00 ➝ $53.00	+78.99%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
8/13/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$42.00 ➝ $41.00	+37.45%
Get the Latest News and Ratings for IMVT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.
8/8/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$51.00 ➝ $46.00	+65.17%
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$48.00	+47.69%
3/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+58.73%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$55.00	+45.50%
12/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$49.00 ➝ $51.00	+31.61%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+25.69%
10/24/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$28.00 ➝ $57.00	+64.74%
9/27/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00 ➝ $48.00	+14.75%
9/27/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$33.00 ➝ $50.00	+25.13%
7/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$28.00 ➝ $34.00	+47.00%
7/10/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Barcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
2/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$14.00 ➝ $21.00	+18.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:53 AM ET.

IMVT Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunovant is $47.22, with a high forecast of $55.00 and a low forecast of $36.00.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMVT shares.
: According to analysts, Immunovant's stock has a predicted upside of 82.61% based on their 12-month stock forecasts.
: Immunovant has been rated by research analysts at HC Wainwright, Oppenheimer, Raymond James, and Wells Fargo & Company in the past 90 days.
: Analysts like Immunovant more than other "medical" companies. The consensus rating for Immunovant is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMVT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

>> Register for the Workshop Now

This page (NASDAQ:IMVT) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Stock Forecast & Price Target